McKesson Recalls Amgen's EVENITY Due to Cold Chain Failures: A Recurring Distribution Risk
McKesson Medical-Surgical Inc. is conducting a voluntary Class II recall of Amgen's EVENITY (romosozumab-aqqg) injection due to CGMP deviations and potential temperature excursions during transit. This event, affecting distribution in OH, VA, FL, signals recurring systemic issues in McKesson's cold chain integrity, following similar recalls in 2024. Procurement and regulatory teams must reassess distribution partner compliance to mitigate supply chain risks for temperature-sensitive biologics.
FDA Findings: Summary of EVENITY Recall Due to Cold Chain Breach
McKesson Medical-Surgical Inc. Corporate Office initiated a voluntary Class II recall (D-0539-2025) on April 21, 2025, for Amgen Inc.'s EVENITY (romosozumab-aqqg) injection. The recall specifically targets Lot 1178382, with an expiration date of March 31, 2027, identified by NDC 55513-880-02. The primary reasons cited for this action are Current Good Manufacturing Practice (CGMP) deviations and potential temperature excursions that occurred during transit delays. This breach in cold chain integrity for a critical biologic like romosozumab-aqqg raises significant concerns about product stability and efficacy. The affected product, a 105mg/1.17 mL subcutaneous injection, was distributed within the U.S., specifically impacting healthcare providers and patients in Ohio, Virginia, and Florida. For procurement directors, this incident necessitates an immediate review of distributor qualification processes and cold chain validation protocols. Regulatory affairs heads must assess the implications of transit-related CGMP failures on product stability data and overall compliance, while supply chain VPs face potential disruptions and increased scrutiny on their distribution partners' adherence to stringent temperature control requirements for sensitive pharmaceutical products.
Impact of McKesson's EVENITY Recall on Biologics Distribution Integrity
The voluntary recall of EVENITY (romosozumab-aqqg) by McKesson Medical-Surgical Inc. underscores critical vulnerabilities within the pharmaceutical distribution network, particularly concerning temperature-sensitive biologics. As a major distributor, McKesson's role is pivotal in maintaining the integrity of products manufactured by companies like Amgen Inc. The identified potential temperature excursions during transit delays for this human prescription drug (BLA761062) can compromise the therapeutic efficacy and safety profile of romosozumab-aqqg, a molecule designed for specific biological activity. While the quantity recalled for this specific lot (Lot 1178382) involved 2 pre-filled syringes, the underlying systemic issue of CGMP deviations in transit is profoundly concerning. For business development executives, this event highlights the reputational risk associated with distribution partners and the potential for market erosion if product quality is compromised. Procurement teams must implement more rigorous temperature monitoring protocols, including real-time data loggers, and conduct frequent, unannounced audits of distributor compliance with storage and transit requirements, especially for high-value, temperature-sensitive biologics to safeguard patient outcomes and brand trust.
Supply Chain Exposure: Romosozumab-aqqg Availability and Manufacturer Reliance
The recall of EVENITY (romosozumab-aqqg) directly impacts the supply chain for this Amgen Inc. manufactured product, a crucial human prescription drug (BLA761062) for subcutaneous use. While the immediate impact on overall availability for romosozumab-aqqg across the entire U.S. market may be limited given the specific lot and quantity involved (2 pre-filled syringes from Lot 1178382), the incident exposes the reliance of manufacturers like Amgen on their distribution partners to uphold product quality post-manufacturing. Any compromise in the cold chain, as indicated by the potential temperature excursions, can lead to product degradation, rendering the drug ineffective or potentially harmful. This creates a direct risk for patient access and continuity of care in the affected states of Ohio, Virginia, and Florida. Supply chain VPs must evaluate the resilience and redundancy of their distribution networks, particularly for single-source biologics where alternative immediate supply options are scarce. Regulatory affairs teams need to assess the potential for broader regulatory action or increased scrutiny on Amgen's distribution oversight, ensuring that the manufacturer's responsibility extends to the point of patient delivery, thereby protecting market access and patient safety.
Mitigating Risk: Enhanced Due Diligence on Pharmaceutical Distribution Partners
The McKesson recall of EVENITY (romosozumab-aqqg) underscores the critical need for pharmaceutical companies to implement enhanced due diligence and oversight mechanisms for their third-party logistics (3PL) and distribution partners. Given that the knowledge graph does not identify alternative suppliers for romosozumab-aqqg, the focus for risk mitigation shifts to strengthening distribution practices. This includes comprehensive auditing of temperature-controlled storage facilities, rigorous validation of transit routes and packaging solutions, and the establishment of robust emergency contingency plans for cold chain failures. Procurement directors must review and update service level agreements (SLAs) with distributors to incorporate explicit, measurable clauses on temperature monitoring, deviation reporting, and clear accountability for product loss or degradation due to transit failures. Furthermore, supply chain VPs should explore strategies such as diversifying distribution channels or implementing direct-to-pharmacy models for high-value, temperature-sensitive products where feasible. This proactive approach minimizes reliance on single points of failure and ensures that product integrity is maintained from manufacturing site to patient, thereby safeguarding investment in product development and market reputation.
McKesson's Pattern of Recurring Distribution Compliance Challenges
The current recall of EVENITY (romosozumab-aqqg) by McKesson Medical-Surgical Inc. is not an isolated incident but rather indicative of a concerning pattern of distribution compliance challenges within the company. ChemLifeIntel's intelligence graph reveals two prior, similar recalls initiated by McKesson in March 2024. These included Pfizer's Bicillin L-A and Infuvite Adult Multiple Vitamins, both of which specifically cited "Critical Distributor Storage Compliance Gaps." This historical context directly parallels the reasons for the current EVENITY recall, which are attributed to "CGMP Deviations; potential temperature excursions due to transit delays." The recurrence of these issues, all pointing to systemic failures in maintaining product integrity during storage and transit, suggests a persistent challenge in McKesson's operational controls. For regulatory affairs heads, this established pattern serves as a significant red flag, signaling a higher likelihood of increased FDA scrutiny and potential for more stringent enforcement actions. Procurement directors must immediately initiate comprehensive reviews of all existing contracts with McKesson, particularly for temperature-sensitive or high-value pharmaceutical products, to proactively assess and mitigate ongoing supply chain risks across their portfolio and protect patient safety.
Remediation Timeline and Anticipated Regulatory Oversight for McKesson
The voluntary Class II recall of EVENITY (romosozumab-aqqg) by McKesson Medical-Surgical Inc. is currently ongoing, with the recall initiation date recorded as April 21, 2025. The FDA's Center Classification Date of July 21, 2025, followed by the report date of July 30, 2025, confirms active regulatory oversight of this event. McKesson is now obligated to conduct a thorough root cause analysis to identify the fundamental reasons behind the CGMP deviations and temperature excursions, and subsequently implement robust corrective and preventive actions (CAPA). Given the documented history of similar distribution compliance issues, as evidenced by prior recalls in March 2024 for Pfizer's Bicillin L-A and Infuvite Adult Multiple Vitamins, McKesson faces heightened regulatory scrutiny from the FDA. Supply chain VPs and regulatory affairs heads must anticipate that the FDA will closely monitor the effectiveness and sustainability of McKesson's remediation efforts. Failure to adequately address these systemic issues could lead to further recalls, more severe enforcement actions, or even restrictions on McKesson's distribution capabilities for certain product categories, which would significantly impact numerous pharmaceutical clients relying on their services and potentially disrupt broader market access for critical medicines.